• Natera released a press release on a JAMA Dermatology study comparing Signatera MRD with AMERK in Merkel cell carcinoma surveillance.
• Head-to-head analysis in 169 patients showed Signatera was a stronger recurrence predictor than AMERK (HR difference 6.6; p < 0.001).
• Signatera sensitivity was 90% versus 55% for AMERK, with earlier detection in dual-positive cases (median lead time 5.1 months versus 2.1 months).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260722520063) on July 22, 2026, and is solely responsible for the information contained therein.